Recently, the FDA established a program to try and help stem abuse of extended-release opiod painkillers. Millions of Americans use opiod painkillers, which include extended-release and patch formulations, such as extended-release OxyContin and Opana, as well as the Duragesic patch. Pharmaceutical manufacturers must develop new programs to prevent misuse of these powerful drugs. Such programs will likely involve new hurdles for patients seeking these medications and for doctors prescribing them.
Comments are closed.